Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
AEON Biopharma, Inc. (AEON) had Stock-Based Compensation of $3.73M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-4.54M |
|
-- |
|
-- |
|
$2.49M |
|
$-2.49M |
|
$-2.04M |
|
$-4.54M |
|
$-4.54M |
|
$-4.54M |
|
$-4.54M |
|
$-4.54M |
|
$-4.54M |
|
$-2.49M |
|
$-2.47M |
|
11.63M |
|
11.63M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$7.41M |
|
$0.18M |
|
$1.32M |
|
$8.73M |
|
$8.23M |
|
$17.05M |
|
$20.38M |
|
$28.61M |
|
$-19.87M |
|
$-19.87M |
|
$-19.87M |
|
11.64M |
|
| Cash Flow Statement Financials | |
$-12.60M |
|
$-0.00M |
|
$18.51M |
|
$0.01M |
|
$5.93M |
|
$5.91M |
|
|
Stock-Based Compensation |
$3.73M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.90 |
|
-- |
|
-- |
|
-6.04 |
|
-0.86 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
22.84% |
|
22.84% |
|
-51.96% |
|
160.87% |
|
$-1.71 |
|
$-1.08 |
|
$-1.08 |
|